文献速递造血干细胞移植与细胞治疗

同种异体反应性:造血干细胞移植的双面性

Alloreactivity: the Janus-face of hematopoietic stem cell transplantation.
PubMed 文献 · Leukemia · 2017-03-08

该回顾性队列分析纳入32838例异基因造血干细胞移植患者,以59692例自体移植患者为参照,发现随供受体抗原差异减小,非复发死亡率系统性下降,总生存和无复发生存逐步提高,且在各主要疾病及分期中一致。结果提示同种异体反应性的有害效应随错配增加而叠加,有益效应得以保留,若有选择应选最佳匹配供者。

要点

  • 随供受体表型和基因型抗原差异减小,非复发死亡率显著系统性下降。
  • 非复发死亡率下降伴随总生存和无复发生存逐步提高。
  • 该效应在所有主要疾病和疾病分期类别中均一致。

核心结论

  • 同种异体反应性的有害效应随每一步错配而叠加,有益效应得以保留。
  • 若有选择,最佳匹配应为首选供者。
  • 数据支持加强寻找可预测「无移植物抗宿主病」的基因组和环境因素。

研究设计与样本

  • 回顾性分析预设队列32838例异基因造血干细胞移植患者,以59692例自体造血干细胞移植患者为参照组。

主要发现

  • 随表型和基因型抗原差异减小,非复发死亡率显著且系统性下降,同时总生存和无复发生存逐步提高。
  • 5年累积超额事件率的Spearman相关系数分别为0.964(P<0.00)和0.976(P<0.00)。
  • 该系统性逐步效应在所有主要疾病和疾病分期类别中均观察到。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Differences in major and minor histocompatibility antigens between donor and recipient trigger powerful graft-versus-host reactions after allogeneic hematopoietic stem cell transplantation (HSCT). The clinical effects of alloreactivity present a Janus-face: detrimental graft-versus-host disease increases non-relapse mortality, beneficial graft-versus-malignancy may cure the recipient. The ultimate consequences on long-term outcome remain a matter of debate. We hypothesized that increasing donor-recipient antigen matching would decrease the negative effects, while preserving antitumor alloreactivity. We analyzed retrospectively a predefined cohort of 32 838 such patients and compared it to 59 692 patients with autologous HSCT as reference group. We found a significant and systematic decrease in non-relapse mortality with decreasing phenotypic and genotypic antigen disparity, paralleled by a stepwise increase in overall and relapse-free survival (Spearman correlation coefficients of cumulative excess event rates at 5 years 0.964; P<0.00; respectively 0.976; P<0.00). We observed this systematic stepwise effect in all main disease and disease-stage categories. The results suggest that detrimental effects of alloreactivity are additive with each step of mismatching; the beneficial effects remain preserved. Hence, if there is a choice, the best match should be donor of choice. The data support an intensified search for predictive genomic and environmental factors of 'no-graft-versus-host disease'.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Gratwohl A, Sureda A, Cornelissen J, et al. Alloreactivity: the Janus-face of hematopoietic stem cell transplantation. Leukemia. 2017. PMID: 28270691. doi:10.1038/leu.2017.79

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。